Workflow
SANXING(601567)
icon
Search documents
三星医疗(601567) - 2018 Q3 - 季度财报
2018-10-30 16:00
Financial Performance - Operating revenue for the first nine months rose by 21.35% to CNY 4.21 billion year-on-year[6] - Net profit attributable to shareholders decreased by 0.87% to CNY 415.25 million compared to the same period last year[6] - Total operating revenue for the third quarter reached ¥1,623,585,269.04, an increase of 10.8% compared to ¥1,464,995,478.08 in the same period last year[27] - Net profit for the third quarter was ¥209,028,691.91, representing a 9.4% increase from ¥190,770,604.44 in the previous year[29] - The company reported a total profit of ¥262,521,253.30 for the third quarter, up 8.2% from ¥242,735,981.73 year-on-year[29] Cash Flow - Net cash flow from operating activities dropped significantly by 74.27% to CNY 66.54 million[6] - Cash inflow from operating activities totaled ¥3,145,841,493.17, down 56.5% from ¥7,233,716,941.21 in the same period last year[39] - Cash outflow from operating activities decreased to ¥1,886,699,033.81, compared to ¥7,885,027,580.05 in the previous year, reflecting a reduction of approximately 76%[39] - Cash inflow from investment activities was ¥12,456,509.85, compared to ¥7,213,551.00 in the previous year, showing an increase of 73%[39] - Cash outflow from financing activities totaled ¥6.56 billion, compared to ¥3.86 billion in the same period last year, indicating a significant increase in financing activities[37] Assets and Liabilities - Total assets increased by 20.02% to CNY 15.25 billion compared to the end of the previous year[6] - The total current assets reached RMB 7,276,987,566.51, up from RMB 5,587,073,609.83 in the previous period[20] - Current liabilities rose to ¥5,292,964,618.81, compared to ¥3,923,184,164.46, reflecting an increase of about 35.0%[21] - Non-current liabilities increased to ¥2,345,342,590.99 from ¥1,202,563,575.32, marking a growth of approximately 95.0%[21] - The total liabilities reached ¥7,638,307,209.80, compared to ¥5,125,747,739.78, marking an increase of approximately 49.0%[21] Shareholder Information - The total number of shareholders reached 25,804 by the end of the reporting period[10] - The largest shareholder, Aux Group Co., Ltd., holds 32.08% of the shares[10] - The company repurchased a total of 9,000,800 shares, representing 0.631% of the total share capital, with an average price range of RMB 6.77 to RMB 7.30 per share[15] - The company has implemented a share repurchase plan to enhance market confidence and support the stock price[16] Expenses - Management expenses rose by 73.24% to RMB 353,246,470.22, primarily due to increased medical investments and stock incentive costs[14] - Research and development expenses for the third quarter were ¥63,495,197.90, an increase of 17.3% compared to ¥53,752,014.83 in the same period last year[29] - Sales expenses for the third quarter were ¥111,787,054.09, a decrease of 10.6% from ¥125,101,886.37 in the previous year[27] Other Financial Metrics - The weighted average return on equity decreased by 0.7 percentage points to 5.23%[7] - Basic and diluted earnings per share both decreased by 3.33% to CNY 0.29[7] - The gross profit margin for the third quarter was approximately 7.7%, compared to 10.5% in the same period last year, indicating a decline in profitability[27] - The company's retained earnings decreased to ¥708,328,121.22 from ¥1,011,814,317.61, a decline of about 30.0%[25] - Non-recurring gains and losses totaled CNY 10.50 million for the current period[9] Future Outlook - The company has not disclosed any new product developments or market expansion strategies in this report[5] - The company plans to continue expanding its market presence and invest in new product development to drive future growth[29]
三星医疗(601567) - 2018 Q2 - 季度财报
2018-08-27 16:00
Financial Performance - The company reported no profit distribution during the reporting period[4]. - The company's operating revenue for the first half of the year reached ¥2,586,173,783.92, representing a 29.04% increase compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 9.37% to ¥209,886,666.15 from ¥231,590,543.96 in the previous year[20]. - The net cash flow from operating activities was negative at -¥29,041,652.03, contrasting with a positive cash flow of ¥25,357,993.32 in the same period last year[20]. - The total assets increased by 18.21% to ¥15,024,093,681.29 compared to the end of the previous year[20]. - The basic earnings per share decreased by 6.25% to ¥0.15 from ¥0.16 in the previous year[21]. - The company achieved a revenue of 2,586.17 million yuan in the first half of 2018, representing a growth of 29.04% compared to the previous year[45]. - The net profit attributable to shareholders was 209.89 million yuan, a decrease of 9.37% year-on-year[45]. - Operating costs increased by 31.50% year-on-year to ¥1,766,261,129.51, primarily due to the growth in operating revenue[49]. - Research and development expenses rose by 17.57% to ¥115,146,908.21, driven by increased investment in product innovation and talent acquisition[49]. - The company reported a net cash flow from operating activities of -¥29,041,652.03, a decline of 214.53% compared to the previous year[49]. - The company reported a decrease in accounts payable to CNY 1,249,360,635.18 from CNY 1,106,883,059.73, a decline of approximately 12.9%[111]. - The net profit for the first half of 2018 was ¥205,987,995.60, a decrease of 13.0% from ¥236,900,008.39 in the previous year[116]. - The company's total liabilities increased to ¥2,201,211,962.07, compared to ¥1,364,144,458.48 in the prior period, reflecting a growth of 61.2%[114]. - Total equity decreased to ¥6,047,545,083.64 from ¥6,405,132,849.18, indicating a decline of 5.6%[114]. Governance and Compliance - The financial report has not been audited, ensuring transparency in the financial statements[5]. - The company guarantees the accuracy and completeness of the semi-annual report, with legal responsibility for any misrepresentation[5]. - The company has a structured governance with a board of directors and supervisory board ensuring oversight[5]. - The company maintains a consistent communication channel with stakeholders through designated contacts[14]. - The company’s financial statements comply with the requirements of the accounting standards, reflecting its financial status and operational results accurately[150]. - The company prepares consolidated financial statements based on its own and subsidiaries' financial reports, reflecting the overall financial position, operating results, and cash flows of the entire corporate group[157]. Strategic Focus and Future Plans - The company is focused on expanding its smart power distribution and medical service sectors, with a strategy to build an integrated service platform for hospitals[26][27]. - The company plans to leverage various development models, including mergers and acquisitions, to enhance its medical service offerings and expand its market presence[27]. - The company aims to establish a closed-loop ecosystem in the medical industry by integrating hospital services, online healthcare, and medical insurance[27]. - The company is focusing on expanding its medical services through a "three medical linkage" strategy, enhancing its investment in comprehensive hospitals and specialized medical facilities[42]. - The company plans to expand its market presence and invest in new product development to drive future growth[116]. Risks and Challenges - The company faces management risks due to rapid expansion and entry into the healthcare industry, necessitating the recruitment and retention of management and technical talent[62]. - The company is exposed to market competition risks in the electric meter and transformer sectors, which could adversely affect profitability[63]. - The company relies heavily on domestic power system users, making it vulnerable to changes in national policies and investment scales[64]. - The company is engaged in overseas investments, which carry legal and operational risks due to differing regulations and environments[65]. - The company has significant risks associated with its financing leasing business, including potential defaults by lessees[69]. Shareholder Information - The company reported a total of 25,998 common stock shareholders by the end of the reporting period[95]. - The largest shareholder, Aux Group Co., Ltd., holds 457,719,653 shares, accounting for 32.08% of the total shares[96]. - The second-largest shareholder, Zheng Jianjiang, holds 235,036,730 shares, representing 16.47% of the total shares[96]. - The top ten unrestricted shareholders include Aux Group Co., Ltd. with 457,719,653 shares and Zheng Jianjiang with 235,036,730 shares, highlighting concentrated ownership[97]. - The company’s top ten restricted shareholders have a total of 2,000,000 shares that will become tradable on January 4, 2019, subject to performance conditions[99]. Cash Flow and Liquidity - The company reported a net cash flow from financing activities of CNY 1,519,298,276.30, compared to a negative CNY -363,101,767.13 in the same period last year, showing a substantial improvement[124]. - The company's cash and cash equivalents at the end of the period amounted to CNY 1,850,749,936.26, up from CNY 1,722,008,531.13 at the end of the previous year[124]. - The net cash flow from investing activities was -¥452,398,653.35, a decrease from -¥687,745,186.29 in the previous period[127]. - Cash inflow from financing activities totaled ¥2,527,974,411.00, compared to ¥1,332,000,567.38 in the prior period, indicating a significant increase[127]. - The total cash and cash equivalents at the end of the period amounted to ¥447,998,279.78, a decrease from ¥667,479,133.61 in the previous period[127]. Asset Management - Total assets increased to CNY 15,024,093,681.29, up from CNY 12,709,803,764.76, representing a growth of approximately 18.2% year-over-year[110]. - Current assets totaled CNY 7,318,529,433.18, compared to CNY 5,587,073,609.83, reflecting an increase of about 31%[110]. - Accounts receivable rose to CNY 1,800,236,664.60 from CNY 1,495,282,947.19, marking an increase of approximately 20.4%[110]. - Inventory increased significantly to CNY 1,026,905,765.88, up from CNY 589,792,383.71, a growth of around 74.5%[110]. - Long-term investments in equity rose to CNY 3,859,396,415.14 from CNY 3,398,865,836.50, an increase of approximately 13.5%[113]. Environmental and Social Responsibility - The company’s environmental activities comply with national regulations, with no major environmental incidents reported during the reporting period[86]. Subsidiaries and Operational Structure - The company operates in the medical project investment and hospital management sectors, as well as in the manufacturing and sales of various electrical and measurement equipment[143]. - The company’s subsidiaries include Ningbo Aokex High-tech Co., Ltd., Ningbo Samsung Intelligent Electric Co., Ltd., and several others, indicating a diverse operational structure[144][145].
三星医疗(601567) - 2017 Q4 - 年度财报
2018-04-23 16:00
Financial Performance - The company reported a net profit of CNY 344,155,496.50 for the year 2017, with a 10% statutory reserve fund allocation of CNY 34,415,549.65[5]. - The total distributable profit at the end of 2017 was CNY 1,011,814,317.61 after accounting for the previous year's dividend payment of CNY 425,530,804.20[5]. - The company plans to distribute a cash dividend of CNY 3 per 10 shares to all shareholders, with the remaining profit carried forward to the next year[5]. - The company's operating revenue for 2017 was CNY 5,368,397,769.60, representing a 9.08% increase compared to CNY 4,921,721,348.01 in 2016[22]. - The net profit attributable to shareholders for 2017 was CNY 890,589,037.28, a 12.13% increase from CNY 794,248,499.29 in 2016[22]. - The basic earnings per share for 2017 was CNY 0.63, up 5.00% from CNY 0.60 in 2016[23]. - The company's total assets at the end of 2017 were CNY 12,709,803,764.76, a 9.22% increase from CNY 11,636,628,474.95 at the end of 2016[22]. - The net cash flow from operating activities for 2017 was CNY 933,506,116.98, reflecting a 5.86% increase compared to CNY 881,845,470.14 in 2016[22]. - The company reported a non-recurring gain of CNY 152,454,737.26 in 2017, compared to CNY 171,555,768.00 in 2016[26]. - The weighted average return on equity for 2017 was 12.35%, down 2.95 percentage points from 15.30% in 2016[23]. - The company's net assets attributable to shareholders at the end of 2017 were CNY 7,516,494,968.79, a 9.68% increase from CNY 6,852,861,710.54 at the end of 2016[22]. - The company achieved quarterly revenues of CNY 1,899,260,261.25 in Q4 2017, contributing to a total annual revenue growth[24]. Investments and Acquisitions - The company acquired 100% equity of Zhejiang Mingzhou Rehabilitation Hospital for RMB 320 million and Wenzhou Deep Blue Hospital for RMB 91 million during the reporting period[37]. - The company plans to invest ¥136,528.65 million in the construction of 300 grassroots medical institutions in Ningbo[85]. - The company is actively pursuing a strategy of integrating quality resources in the medical sector through new establishments, investments, and acquisitions[104]. - The financing leasing business reported a total new investment of CNY 3,224 million in 2017, with medical leasing accounting for CNY 3,004 million[62]. - The asset scale of the financing leasing company increased to CNY 5,504 million by the end of the year, marking a year-on-year growth of 47.88%[62]. Market and Growth Opportunities - The smart meter market is expected to grow at an annual rate of approximately 15%, with a projected demand of 40.94 million smart meters per year by 2020[34]. - The number of private hospitals in China increased from 7,068 in 2010 to 14,518 in 2015, with a compound annual growth rate of 15.5%[35]. - The total investment in the distribution network during the 13th Five-Year Plan period is expected to exceed RMB 1.7 trillion, providing new opportunities for related enterprises[34]. - The company aims to achieve CNY 10 billion in revenue from smart power distribution by 2020, positioning itself as a leading provider of smart power solutions in China[94]. - The smart energy meter market in China has a demand exceeding CNY 16 billion annually, with an expected user base of 480 million for the State Grid by 2020[92]. Risk Management - The company has detailed risks associated with its future development in the report, which investors should review[7]. - The company emphasizes the importance of investment risk awareness in its forward-looking statements[6]. - The company faces significant competition in the electric meter and 10kV distribution transformer markets, which may adversely affect profitability if competitors increase production capacity and reduce costs[106]. - The company relies heavily on domestic power system users, which exposes it to risks related to national industrial policies and investment scales[107]. - The company is engaged in overseas mergers and acquisitions, which carry investment and operational risks due to differing legal and commercial environments[108]. - The company is investing in new hospitals, which involves high initial costs and long payback periods, presenting risks of not recovering investments[109]. - The company has experienced growth in its financing leasing business, but faces risks related to lessees' inability to pay rent on time[111]. - The company has established a scientific and efficient management system to mitigate management risks associated with its expanding operations[105]. Corporate Governance - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[4]. - The report confirms the attendance of all board members at the board meeting, ensuring accountability for the report's accuracy[8]. - The company appointed Lixin Accounting Firm with an audit fee of CNY 1,833,800 for the year, maintaining a long-term relationship of 11 years[121]. - The company held two shareholder meetings during the reporting period, both of which were legally witnessed and compliant with regulations[182]. - The board of directors consists of 3 independent directors who actively fulfill their responsibilities and provide independent opinions on related transactions[183]. - The supervisory board effectively supervises the company's operational decisions and financial status, ensuring compliance and protecting shareholder interests[184]. - The company has no instances of non-operational fund occupation by controlling shareholders or related parties during the reporting period[186]. - The company strictly adheres to legal requirements for information disclosure, completing all necessary reports and announcements in a timely manner[187]. Shareholder Information - The largest shareholder, Aux Group Co., Ltd., holds 457,719,653 shares, representing 32.28% of the total shares[157]. - Zheng Jianjiang, the actual controller, holds 235,036,730 shares, accounting for 16.57% of the total shares[157]. - The total number of ordinary shares decreased from 1,418,806,914 to 1,418,026,289 shares due to the repurchase and cancellation of 780,625 restricted shares[153]. - The total number of shareholders decreased from 27,572 to 26,925 during the reporting period[154]. - The company has no strategic investors or general legal entities that have become top ten shareholders through new share placements[161]. Employee and Management Information - The number of employees in the parent company is 1,766, while the number in major subsidiaries is 3,721, totaling 5,487 employees[177]. - The company has 2,244 production personnel, 557 sales personnel, 2,152 technical personnel, 125 financial personnel, and 409 administrative personnel[177]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to 2.9421 million yuan[173]. - The company organized various training programs for executives, middle management, sales personnel, and new employees to enhance their skills and loyalty[179].
三星医疗(601567) - 2018 Q1 - 季度财报
2018-04-23 16:00
Financial Performance - Operating revenue for the period reached CNY 1.15 billion, a 24.46% increase year-on-year[6] - Net profit attributable to shareholders was CNY 99.76 million, reflecting a 2.61% increase from the same period last year[6] - The company reported a basic earnings per share of CNY 0.07, unchanged from the previous year[6] - The company's operating revenue for Q1 2018 was CNY 357,326,045.85, an increase of 17.5% compared to CNY 304,184,119.45 in the same period last year[29] - The net profit for Q1 2018 was CNY 99,742,823.52, slightly up from CNY 98,990,883.91, reflecting a growth of 0.76% year-over-year[27] - The company reported a total profit of CNY 133,575,711.87 for Q1 2018, up from CNY 126,105,840.05 in the previous year, marking a growth of 5.8%[27] - The total comprehensive income for Q1 2018 was CNY 80,827,581.41, down from CNY 111,720,124.47 in Q1 2017, indicating a decline of 27.7%[28] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -136.58 million, worsening by 9.09% compared to the previous year[6] - Cash flow from operating activities was CNY 1,187,608,952.77 in Q1 2018, slightly down from CNY 1,220,264,304.54 in the previous year[31] - The net cash flow from operating activities was -136,580,517.06 RMB, compared to -125,199,072.06 RMB in the previous period, indicating a decline in operational cash flow[32] - Cash and cash equivalents at the end of the period totaled 1,051,179,426.31 RMB, down from 2,257,518,119.17 RMB in the previous period[33] - The cash flow from operating activities showed a net increase of 382,857,154.32 RMB, a turnaround from -357,639,361.49 RMB in the previous period, indicating improved operational efficiency[35] Assets and Liabilities - Total assets increased by 8.84% to CNY 13.83 billion compared to the end of the previous year[6] - The total current assets reached ¥6,080,940,627.40, up from ¥5,587,073,609.83[17] - Current liabilities rose to ¥4,458,294,005.22, an increase of 13.6% from ¥3,923,184,164.46 at the start of the year[19] - Non-current liabilities totaled ¥1,650,200,799.80, up 37.2% from ¥1,202,563,575.32 at the beginning of the year[19] - The company's equity attributable to shareholders reached ¥7,656,843,854.96, compared to ¥7,516,494,968.79 at the beginning of the year, reflecting a growth of 1.9%[19] Shareholder Information - The number of shareholders reached 27,572, with the top ten shareholders holding a significant portion of shares[9] - The largest shareholder, Aux Group Co., Ltd., holds 32.08% of the shares, totaling 457,719,653 shares[9] Investment and Expenses - Investment income rose by 32.93% to ¥15,038,716.28, mainly from cash dividends received[12] - Sales expenses increased by 36.62% to ¥104,331,026.83, reflecting the company's growth in scale[12] - The company experienced a financial expense of CNY 11,738,202.92 in Q1 2018, compared to a financial income of CNY 3,091,712.61 in the same period last year[27] Other Financial Metrics - The weighted average return on equity decreased by 0.11 percentage points to 1.30%[6] - The gross profit margin improved to 25.4% in Q1 2018, compared to 27.9% in Q1 2017, indicating a decrease in profitability despite higher revenues[29] - The company has not disclosed any new product developments or market expansion strategies in this report[6]
三星医疗(601567) - 2017 Q3 - 季度财报
2017-10-23 16:00
Financial Performance - Operating revenue for the first nine months rose by 9.92% to CNY 3,469,137,508.35 year-on-year[6] - Net profit attributable to shareholders increased by 16.23% to CNY 418,917,199.14 compared to the same period last year[6] - Basic earnings per share increased by 7.14% to CNY 0.30 compared to the same period last year[6] - Total revenue for Q3 2017 reached ¥1,464,995,478.08, an increase of 17.5% compared to ¥1,246,667,127.96 in Q3 2016[23] - Year-to-date revenue for 2017 was ¥3,469,137,508.35, up from ¥3,156,094,214.47 in the same period of 2016, reflecting a growth of 9.9%[23] - Net profit for Q3 2017 reached CNY 190,770,604.44, representing a 20.0% increase from CNY 158,996,939.85 in Q3 2016[25] - Total profit for Q3 2017 was CNY 242,735,981.73, up from CNY 201,830,530.72 in Q3 2016, indicating a growth of 20.3%[25] - The net profit for the first nine months of 2017 reached CNY 175,070,115.79, compared to CNY 107,312,270.19 in the same period of 2016, indicating a year-over-year increase of about 63.3%[29] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 258,578,176.44, a significant improvement from a negative cash flow of CNY 81,512,014.08 in the previous year[6] - Cash flow from operating activities for the first nine months of 2017 was CNY 258,578,176.44, a significant recovery from a negative cash flow of CNY -81,512,014.08 in the same period last year[32] - The company reported total cash inflow from investment activities of CNY 1,071,266,644.98, compared to CNY 681,101,022.45 in the previous year, marking an increase of approximately 57.2%[32] - The net cash flow from financing activities was CNY -303,125,245.40 for the first nine months of 2017, a decrease from a positive cash flow of CNY 2,886,675,452.82 in the same period of 2016[32] - The company reported a total operating cash outflow of CNY 3,914,770,446.39 for the first nine months of 2017, compared to CNY 3,605,226,733.76 in the same period last year[32] Assets and Liabilities - Total assets increased by 2.64% to CNY 11,943,343,590.62 compared to the end of the previous year[6] - The total current assets decreased to ¥6,057,973,444.20 from ¥6,434,798,711.42[17] - Total liabilities increased to ¥5,030,063,686.57 from ¥4,712,823,189.98, marking a rise of 6.7%[19] - Current liabilities totaled ¥3,691,094,175.69, compared to ¥3,606,782,475.01, reflecting an increase of 2.3%[19] - The company's long-term borrowings rose by 66% to ¥894,377,446.63 from ¥537,964,457.33, driven by financing lease project investments[12] Shareholder Information - The total number of shareholders at the end of the reporting period was 25,783[10] - The largest shareholder, Aux Group Co., Ltd., holds 32.27% of the shares[10] Government Support and Non-Recurring Items - The company received government subsidies amounting to CNY 10,320,837.20 during the reporting period[8] - Non-recurring gains and losses totaled CNY 12,706,280.61 for the first nine months[9] Inventory and Receivables - Accounts receivable decreased by 79% to ¥23,756,188.48 from ¥113,134,922.47, mainly due to the endorsement transfer of receivables[12] - Inventory increased by 62% to ¥857,930,446.47 from ¥528,696,412.15, reflecting a rise in raw material and finished goods reserves[12] - Other receivables increased by 104% to ¥174,946,257.82 from ¥85,817,286.91, primarily due to higher bid and performance guarantee deposits[12] Financial Ratios - The weighted average return on equity decreased by 1.92 percentage points to 5.93%[6]
三星医疗(601567) - 2017 Q2 - 季度财报
2017-08-21 16:00
Financial Performance - The company reported no profit distribution during the reporting period[2]. - The company's operating revenue for the first half of the year reached ¥2,004,142,030.27, representing a 4.96% increase compared to ¥1,909,427,086.51 in the same period last year[18]. - Net profit attributable to shareholders was ¥231,590,543.96, up 13.65% from ¥203,778,714.86 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥218,977,645.87, reflecting a 17.94% increase from ¥185,669,416.96 in the previous year[18]. - The company reported a net cash flow from operating activities of ¥25,357,993.32, a significant recovery from a negative cash flow of ¥92,992,955.73 in the same period last year[18]. - Basic earnings per share decreased by 5.88% to ¥0.16 from ¥0.17 year-on-year[20]. - The weighted average return on equity dropped to 3.32%, down 2.21 percentage points from 5.53% in the previous year[20]. - The total assets at the end of the reporting period were ¥11,488,055,077.25, a decrease of 1.28% from ¥11,636,628,474.95 at the end of the previous year[19]. - The company achieved a revenue of 2,004,142,030.27 CNY in the first half of 2017, representing a year-on-year growth of 4.96%[58]. - The net profit attributable to shareholders reached 231,590,500 CNY, an increase of 13.65% compared to the same period last year[49]. - The company reported a significant increase in prepayments from CNY 77,830,250.06 to CNY 138,325,828.91, an increase of about 77.6%[112]. - The company reported a net profit of approximately ¥8.61 million for its wholly-owned subsidiary in the power product manufacturing sector[71]. Business Operations and Strategy - The company operates under the name Ningbo Sanxing Medical Electric Co., Ltd. and is listed on the Shanghai Stock Exchange with the stock code 601567[16]. - The company is actively developing smart power distribution products and expanding its market presence through various strategies, including mergers and acquisitions in the healthcare sector[24][25]. - The company aims to enhance its integrated hospital service platform and expand its operations both domestically and internationally, focusing on high-quality medical resources[25]. - The company has established a strong brand presence with its products recognized by major power companies, enhancing its competitive edge in the market[36]. - The company has a comprehensive product line covering the entire smart power distribution industry chain, providing superior solutions in the field of electricity distribution and consumption[37]. - The company has invested in advanced manufacturing and information management systems, creating a smart digital factory that enhances production efficiency and quality control[41]. - The company has implemented a partner mechanism to foster collaboration with renowned medical professionals, enhancing its healthcare service capabilities[46]. - The company is focusing on integrating information technology into healthcare services, achieving a non-window registration rate of over 65% through various self-service channels[55]. - The company aims to enhance its market presence through strategic partnerships with top medical institutions, improving management and operational capabilities[54]. - The company is actively pursuing mergers and acquisitions in the healthcare sector to strengthen its integrated medical service offerings[52]. Financial Position and Assets - The total assets of Aux Group's wholly-owned subsidiary, Aux Medical Group, reached CNY 82,525.24 million, with a net asset value of CNY 78,014.12 million and a net profit of CNY -327.1 million as of June 30, 2017[4]. - The financing leasing subsidiary reported total assets of CNY 417,480.63 million, net assets of CNY 159,542.9 million, and a net profit of CNY 7,463.59 million for the same period[4]. - Aux Group's total assets amounted to CNY 38,753.94 million, with net assets of CNY 38,705.7 million and a net profit of CNY -60.45 million as of June 30, 2017[4]. - The company has committed to invest ¥136.53 million in the construction of 300 grassroots medical institutions, with no funds utilized in the current year[68]. - The fair value of financial assets held by the company includes 50 million shares of Hong Kong Medical Group valued at approximately HKD 132 million[70]. - The total number of shares issued by the company is 141,880.6914 million, with a registered capital of 141,880.6914 million yuan[142]. - The company has a total of 220,208,664.00 in shareholder contributions, indicating strong investor confidence[140]. Shareholder Information - The total number of ordinary shareholders was 29,637 at the end of the reporting period[100]. - The largest shareholder, Aux Group Co., Ltd., held 457,719,653 shares, representing 32.26% of total shares[102]. - The second-largest shareholder, Zheng Jianjiang, held 235,036,730 shares, accounting for 16.57%[102]. - The third-largest shareholder, Zheng Jiang, had 65,500,000 shares, with 4.62% ownership, and 25,000,000 shares pledged[102]. - The total number of shares held by the top ten shareholders was significant, indicating concentrated ownership[102]. - The company reported no preferred shareholders with restored voting rights at the end of the reporting period[100]. Legal and Compliance - The board of directors and senior management confirmed the accuracy and completeness of the semi-annual report[4]. - The semi-annual report has not been audited[4]. - The company has not faced any major litigation or arbitration matters during the reporting period, reflecting a stable legal standing[4]. - The company’s actual controller and shareholders have made commitments to avoid direct or indirect competition with the company, ensuring a focused business strategy[4]. - The company has approved a daily related party transaction amount not exceeding CNY 6,500 million for the fiscal year 2017[4]. - The company has not disclosed any significant updates regarding employee stock ownership plans or other incentive measures during the reporting period[4]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards and reflect the company's financial position and operating results accurately[149]. - The company includes all subsidiaries in its consolidated financial statements based on control[155]. - The company follows specific accounting policies and estimates tailored to its operational characteristics[148]. - The company recognizes the income, expenses, and cash flows of newly acquired subsidiaries from the acquisition date to the end of the reporting period[157]. - The company ensures that all subsidiaries adopt consistent accounting policies and periods for consolidation purposes[156]. - The company will remeasure the remaining equity investment at fair value on the date of losing control over the invested entity, with the investment income recognized in the current period[159].
三星医疗(601567) - 2016 Q4 - 年度财报
2017-04-17 16:00
Financial Performance - The company reported a net profit of CNY 373,930,955.36 for the year 2016, with a statutory reserve of 10% amounting to CNY 37,393,095.54, resulting in a total distributable profit of CNY 1,127,605,174.96 at year-end [2]. - The profit distribution plan for 2016 proposes a cash dividend of CNY 3 per 10 shares (tax included) to all shareholders, with the remaining profit carried forward to the next year [2]. - The company's operating revenue for 2016 was CNY 4,921,721,348.01, an increase of 18.37% compared to CNY 4,158,057,000.63 in 2015 [21]. - The net profit attributable to shareholders for 2016 was CNY 794,248,499.29, representing a growth of 40.84% from CNY 563,954,720.89 in 2015 [21]. - The net cash flow from operating activities increased by 63.06% to CNY 881,845,470.14 in 2016, up from CNY 540,813,896.48 in 2015 [21]. - The total assets at the end of 2016 reached CNY 11,636,628,474.95, a 56.78% increase from CNY 7,422,093,710.73 in 2015 [21]. - The basic earnings per share for 2016 was CNY 0.60, up 20% from CNY 0.50 in 2015 [22]. - The weighted average return on equity for 2016 was 15.30%, a decrease of 3.84 percentage points from 19.14% in 2015 [22]. - The company reported a net profit of CNY 433,821,695.17 in Q4 2016, with a quarterly revenue of CNY 1,765,627,133.54 [23]. - Non-recurring gains and losses for 2016 totaled CNY 171,555,768.00, compared to CNY 84,829,905.02 in 2015 [26]. Risk Management and Governance - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties during the reporting period [4]. - A standard unqualified audit report was issued by Lixin Accounting Firm, ensuring the financial report's authenticity and completeness [4]. - The company has outlined potential risks in its future development strategies, which are detailed in the "Discussion and Analysis of Operating Conditions" section [5]. - The company emphasizes the importance of investment risk awareness in its forward-looking statements [3]. - The company has a comprehensive risk management framework in place to address potential challenges in its operational strategies [5]. - The company maintains a strong governance structure with all board members present at the board meeting [4]. - The company has engaged Lixin Accounting Firm for auditing services, with a remuneration of RMB 1.6965 million for the audit [103]. - The internal control audit report was issued by Lixin Accounting Firm, confirming the effectiveness of the company's internal controls [170]. - The supervisory board effectively monitored the company's operations and financial status, with no risks identified during the reporting period [168]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth [28]. - The company aims to achieve revenue of 10 billion CNY in the smart distribution and utilization sector by 2020, positioning itself as a leading provider of integrated solutions in this field [86]. - The healthcare segment plans to establish 150 hospitals and other medical service institutions by 2020, with a target of 20,000 hospital beds [87]. - The company is actively expanding its medical services, with the Yinxian Women and Children Hospital expected to open in June 2017, featuring 420 beds [55]. - The company is accelerating the construction of specialized hospitals, ensuring the opening of the Ningbo Women and Children's Hospital by June this year [91]. - The company is actively pursuing mergers and acquisitions in the healthcare sector, establishing investment standards based on multiple dimensions such as revenue and growth potential [90]. Research and Development - The company invested CNY 178 million in R&D, marking a 9.97% increase from the previous year [60]. - The total R&D investment amounted to 178,012,359.2, representing 3.62% of total revenue, with 490 R&D personnel accounting for 9.34% of the total workforce [68]. - The company has a robust R&D capability, continuously innovating in measurement, communication, and energy-saving technologies [41]. - The company has implemented a "100% quality" philosophy, emphasizing quality control from R&D to supply chain management [89]. Shareholder and Capital Structure - The total number of ordinary shares increased to 1,418,806,914 shares due to non-public issuance and stock incentive plans [124]. - The controlling shareholder's ownership percentage decreased from 37.54% to 32.26% during the reporting period [131]. - The total number of ordinary shareholders increased from 29,307 to 30,541 during the reporting period [132]. - The largest shareholder, Aux Group Limited, held 457,719,653 shares, representing 32.26% of total shares [135]. - The company completed a non-public offering and stock buyback during the reporting period [131]. Social Responsibility and Compliance - The company engaged in various public welfare activities, including free medical services through Mingzhou Hospital [118]. - The company emphasized energy conservation and environmental protection in its production processes [118]. - The company provided various levels of training for employees to enhance their skills and adaptability [118]. - The company maintained strict compliance with information disclosure regulations, completing 99 interim announcements during the reporting period [161]. - The company did not encounter any non-operating fund occupation by controlling shareholders or related parties during the reporting period [161]. - The company has no reported penalties from securities regulatory agencies in the past three years [153].
三星医疗(601567) - 2017 Q1 - 季度财报
2017-04-17 16:00
Financial Performance - Operating revenue for the period reached CNY 925,917,712.24, representing a growth of 16.68% year-on-year [6]. - Net profit attributable to shareholders was CNY 87,417,216.97, an increase of 42.05% compared to the same period last year [6]. - Basic earnings per share for the period were CNY 0.07, up 16.67% from CNY 0.06 in the previous year [6]. - The diluted earnings per share were also CNY 0.07, consistent with the basic earnings per share [6]. - Total revenue for Q1 2017 was CNY 925,917,712.24, an increase of 16.67% compared to CNY 793,530,135.26 in the same period last year [25]. - Net profit for Q1 2017 reached CNY 98,990,883.91, an increase of 51.8% compared to CNY 65,228,743.84 in the same period last year [26]. - Operating profit increased to CNY 113,358,297.75, up 71.1% from CNY 66,258,764.15 year-over-year [26]. - The company reported a total comprehensive income of CNY 111,720,124.47 for Q1 2017, compared to CNY 72,789,577.07 in the previous year, marking a growth of 53.4% [27]. - Basic earnings per share for Q1 2017 were CNY 0.07, up from CNY 0.06 in the same quarter last year, reflecting a growth of 16.7% [27]. Cash Flow and Investments - The net cash flow from operating activities was CNY -125,199,072.06, an improvement from CNY -224,523,126.55 in the same period last year [6]. - Cash flow from operating activities increased significantly to CNY 1,220,264,304.54, compared to CNY 884,682,558.53 in the previous year, indicating a growth of 38.0% [32]. - Cash outflow from investing activities amounted to CNY 457,295,958.38, down from CNY 646,659,837.61 in the previous period [33]. - Net cash flow from investing activities was negative at CNY -56,318,299.79, compared to CNY -462,183,248.74 in the previous year [33]. - Cash inflow from financing activities was CNY 277,381,531.99, a decrease from CNY 1,009,505,703.34 year-over-year [34]. - Net cash flow from financing activities was negative at CNY -274,894,976.94, contrasting with a positive CNY 399,948,912.83 in the previous period [34]. - Total cash outflow from operating activities reached CNY 1,499,195,351.93, compared to CNY 1,156,986,674.58 in the previous year [33]. - Cash inflow from sales of goods and services was CNY 354,963,767.46, up from CNY 235,722,224.79 in the previous period [35]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,384,573,893.52, a decrease of 2.17% compared to the end of the previous year [6]. - Total assets decreased from CNY 11,636,628,474.95 at the beginning of the year to CNY 11,384,573,893.52 by the end of Q1 2017, a decline of approximately 2.17% [19]. - Total liabilities decreased from CNY 4,712,823,189.98 to CNY 4,359,164,062.81, representing a reduction of about 7.48% [19]. - Current liabilities decreased from CNY 3,606,782,475.01 to CNY 3,257,492,249.85, a decrease of approximately 9.69% [19]. - Non-current liabilities remained relatively stable, with a slight decrease from CNY 1,106,040,714.97 to CNY 1,101,671,812.96 [19]. - Owner's equity increased from CNY 6,923,805,284.97 to CNY 7,025,409,830.71, reflecting a growth of about 1.47% [19]. Shareholder Information - The total number of shareholders at the end of the reporting period was 29,307 [10]. - The largest shareholder, Aux Group Co., Ltd., held 32.26% of the shares [10]. Other Financial Metrics - The weighted average return on equity decreased by 0.88 percentage points to 1.41% [6]. - The company reported non-recurring gains and losses totaling CNY 9,807,682.20 for the period [9]. - The company's prepaid expenses increased by 50.07% to CNY 116,796,210.47 due to a rise in procurement scale and advance payments to suppliers [13]. - Other receivables rose by 68.08% to CNY 144,242,899.98, primarily due to an increase in bid and performance guarantees [13]. - The company's tax payable decreased by 65.76% to CNY 79,600,119.40, mainly due to the payment of taxes at the beginning of the period [13]. - Investment income surged by 2883.77% to CNY 11,313,454.24, attributed to the adjustment of the investment method from cost to equity for a bank investment [13]. - The company reported a significant decrease in tax and additional charges by 62.61% to CNY 1,457,897.03, mainly due to the implementation of the VAT reform policy [13]. - Sales expenses rose to CNY 76,364,482.68, up 27.2% from CNY 60,000,412.41 year-over-year [26]. - The financial expenses showed a significant improvement, with a net income of CNY -3,091,712.61 compared to CNY 21,369,720.64 in the previous year, indicating a reduction in costs [26]. - Other comprehensive income after tax for Q1 2017 was CNY 12,729,240.56, compared to CNY 7,560,833.23 in the previous year, reflecting a growth of 68.0% [27].
三星医疗(601567) - 2016 Q3 - 季度财报
2016-10-24 16:00
Financial Performance - Operating revenue for the first nine months reached CNY 3,156,094,214.47, a 17.53% increase year-on-year[6] - Net profit attributable to shareholders was CNY 325,879,005.45, representing a 23.04% increase compared to the same period last year[7] - Total operating revenue for Q3 2016 was ¥1,246,667,127.96, an increase of 16.43% compared to ¥1,070,397,352.32 in Q3 2015[31] - Net profit for Q3 2016 reached ¥158,996,939.85, representing a 17.5% increase from ¥135,793,539.07 in Q3 2015[33] - The company reported a total profit of ¥201,830,530.72 for Q3 2016, an increase of 19.9% from ¥168,385,814.53 in Q3 2015[33] - Year-to-date revenue for 2016 reached CNY 1.24 billion, down 4.3% from CNY 1.30 billion in the same period last year[37] - Net profit for Q3 2016 was CNY 54.53 million, a decrease of 13.5% compared to CNY 63.36 million in Q3 2015[38] Assets and Liabilities - Total assets increased by 48.72% to CNY 11,037,798,994.58 compared to the end of the previous year[6] - Total liabilities increased to CNY 4,621,121,530.85 from CNY 4,334,377,322.64, which is an increase of about 6.6%[25] - Total assets as of Q3 2016 amounted to ¥8,196,692,900.15, compared to ¥5,137,711,551.34 in the same period last year, reflecting a growth of 59.96%[29] - Owner's equity increased to ¥6,174,122,146.07 in Q3 2016, up from ¥3,099,478,954.05 in Q3 2015, marking a growth of 99.67%[29] Shareholder Information - The total number of shareholders reached 28,652 by the end of the reporting period[12] - The largest shareholder, Aux Group Co., Ltd., holds 32.26% of the shares[12] - The number of shareholders holding unrestricted shares includes major stakeholders such as Aux Group Limited with 457,719,653 shares[15] Cash Flow - The net cash flow from operating activities was negative at CNY -81,512,014.08 for the first nine months[6] - Operating cash inflow for the first nine months reached ¥3,523,714,719.68, up from ¥2,800,008,913.91 in the previous year, representing a growth of approximately 25.8%[41] - Net cash flow from investment activities was negative at ¥803,549,560.89, improving from a negative ¥1,427,298,152.47 in the previous year[42] - Financing cash inflow amounted to ¥5,264,785,869.85, significantly higher than ¥3,947,071,304.41 in the same period last year, marking an increase of approximately 33.4%[42] Inventory and Receivables - Accounts receivable increased by 204.10% to RMB 103,611,565.22, mainly due to an increase in bill collections[16] - Inventory rose by 99.14% to RMB 878,106,333.55, attributed to increased sales scale and expanded production capacity[17] - The company reported a significant increase in prepayments, which rose to CNY 91,685,837.92 from CNY 43,817,770.29, reflecting a growth of approximately 109.1%[23] Other Financial Metrics - Basic and diluted earnings per share decreased by 3.45% to CNY 0.28[7] - The company reported a significant decrease in investment income, down 83.60% to RMB 10,406,037.69, due to losses from equity investments[17] - The company incurred asset impairment losses of CNY 4.69 million in Q3 2016, compared to CNY 1.43 million in Q3 2015[37] - The company experienced a decrease in other comprehensive income, reporting a loss of ¥1,273,463.21 in Q3 2016 compared to a gain of ¥410,171.62 in Q3 2015[34]